Toxoplasmosis is one of the most dangerous zoonotic diseases, causing serious economic losses worldwide due to abortion and reproductive problems. Vaccination is the best way to prevent disease; thus, it is imperative to develop a candidate vaccine for toxoplasmosis. BAG1 and ROP8 have the potential to become vaccine candidates. In this study, rTgBAG1, rTgROP8, and rTgBAG1‐rTgROP8 were used to evaluate the immune effect of vaccines in each group by detecting the humoral and cellular immune response levels of BABL/c mice after immunization and the ability to resist acute and chronic infection with Toxoplasma gondii (T. gondii). We divided the mice into vaccine groups with different proteins, and the mice were immunized on days 0, 14, and 28. The protective effects of different proteins against T. gondii were analysed by measuring the cytokines, serum antibodies, splenocyte proliferation assay results, survival time, and number and diameter of brain cysts of mice after infection. The vaccine groups exhibited substantially higher IgG, IgG1, and IgG2a levels and effectively stimulated lymphocyte proliferation. The levels of IFN‐γ and IL‐2 in the vaccine group were significantly increased. The survival time of the mice in each vaccine group was prolonged and the diameter of the cysts in the vaccine group was smaller; rTgBAG1‐rTgROP8 had a better protection. Our study showed that the rTgBAG1, rTgROP8, and rTgBAG1‐rTgROP8 recombinant protein vaccines are partial but effective approaches against acute or chronic T. gondii infection. They are potential candidates for a toxoplasmosis vaccine.

中文翻译：

---

重组蛋白 BAG1、ROP8 和 BAG1-ROP8 免疫引起的实验性弓形虫感染的免疫反应和保护作用的比较

弓形虫病是最危险的人畜共患疾病之一，由于流产和生殖问题在全世界造成严重的经济损失。疫苗接种是预防疾病的最佳方法；因此，开发弓形体病候选疫苗势在必行。BAG1和ROP8有潜力成为候选疫苗。本研究采用rTgBAG1、rTgROP8、rTgBAG1‐rTgROP8通过检测BABL/c小鼠免疫后的体液和细胞免疫应答水平以及抵抗急、慢性感染的能力来评价各组疫苗的免疫效果。弓形虫（弓形虫）。我们将小鼠分为不同蛋白的疫苗组，并在第0、14和28天对小鼠进行免疫。不同蛋白对小鼠的保护作用弓形虫通过测定感染后小鼠的细胞因子、血清抗体、脾细胞增殖测定结果、存活时间、脑囊肿数量和直径进行分析。疫苗组表现出显着更高的 IgG、IgG1 和 IgG2a 水平，并有效刺激淋巴细胞增殖。疫苗组的IFN-γ和IL-2水平显着升高。各疫苗组小鼠的存活时间延长，且疫苗组包囊直径更小；rTgBAG1‐rTgROP8 具有更好的保护作用。我们的研究表明，rTgBAG1、rTgROP8 和 rTgBAG1-rTgROP8 重组蛋白疫苗是针对急性或慢性疾病的部分但有效的方法弓形虫感染。它们是弓形体病疫苗的潜在候选者。